Quick-Med Technologies, Inc.

Advanced Technologies for Infection Prevention & Control

March, 2013

Safe Harbor

Forward Looking Statements

This presentation contains forward-looking statements (statements which are not statements of historical facts). Any statements contained in this presentation that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "expects", "plans", "believes", "anticipates", "intends", "estimates", or statements concerning potential opportunities or variations thereof or comparable terminology or the negative thereof should be construed as forward-looking statements involving risks and uncertainties, including without limitation the launch and approval of the potential products described herein and the Company's results of operations. The Company is also subject to other risks as detailed from time-to-time in the Company's SEC filings.

Company Overview

- Quick-Med has developed a disruptive technology—a way to bond antimicrobial agents to various materials
- We are developing and commercializing the world's most advanced antimicrobials
  - Effective / Safe / Non toxic / Non-depleting
- Our technology can revolutionize infection prevention and control by bringing new levels of antimicrobial protection to:
  - Wound Care
  - Catheters
  - Other Medical Devices
  - Consumer Textiles
  - Commercial Textiles
  - Military Textiles
- FDA and EPA approvals granted (2009 and 2011, respectively)
- Recurring revenues with non-recurring costs!

Key Facts

Symbol	QMDT
Corporate Headquarters	Gainesville, FL
Stock Price (10/1/11) || 52-Week Range -	$0.30 || $0.25 - 0.90
Shares Outstanding (6/30/11)	37,246,154
Market Capitalization*	$11,173,846
Volume (daily 90-day average)	3,074
Long-term debt (6/30/11)*	$6,844,865
Cash and accounts receivable (6/30/11)	$1,254,687
Revenue (TTM)*	$1,039,578
EBITDA (TTM)	$(1,983,432)
Insider Ownership	12%
Institutional Ownership Shares	15%
Full-time Employees	10
Fiscal Year	June 30
Accounting Firm	Daszkal Bolton LLP
** Additional details in this presentation*	

Leadership Team

Bernd Liesenfeld, Ph.D *President*	Joined in 2004. Led the development of the Nimbus technology used the Bioguard line of products licensed to Derma Science. Has been involved in all aspects of commercializing Quick-Med's antimicrobial technologies including biochemistry, regulatory and production development.
William Toreki, Ph.D *VP, Research & Development*	Joined in 2002. Served as QMT's Chief Scientist . An experienced researcher and inventor with 20 granted US patents. Responsible for the development of *StayFresh®,* Nimbus®, and NimbuDerm™ antimicrobial technologies.
Paul Jenssen *Chief Financial Officer*	CFO since 2013. 35 years in strategic planning, financial management , and accounting experience including Associated Press – Treasurer; Rothschild North America – COO and Senior Managing Director; Jenssen Consulting – President.
Greg Shultz, Ph.D. *Director & Scientific Advisor*	Professor of Obstetrics/Gynecology and Director of the Institute for Wound Research, College of Medicine at the University of Florida. Past President, Wound Healing Society (1999-2001), PhD Biochemistry, Oklahoma State Univ. Post-doc Cell Biology, Yale
Chris Batich, Ph.D. *Scientific Advisor*	Professor of Biomedical Engineering, and associate Director, Clinical and Translational Science Institute, University of Florida. PhD Organic Chemistry, Rutgers. Post-doc Physical Chemistry, Univ. of Basel

Hospital Infections *A Preventable Epidemic*

Despite considerable attention, hospital infection rates remain alarmingly high

- Millions of nosocomial infections each year
- Longer hospital stays, more complications
- 100,000 deaths in the US annually
- Over $10 billion in additional costs
- Cost reimbursement no longer allowed by Medicare or insurers

“Super-bugs” now a serious community problem in hospitals and the community at large

- MRSA rates are significant and rising
- Slow to diagnose, high cost, high fatality rates

Next Generation Antimicrobials

We are developing the world's most advanced antimicrobials

- Rapid acting and long lasting
- Control both Gram-positive and Gram-negative bacteria (including MRSA, VRE, and other difficult strains)
- New level of safety (non toxic, non leaching, non depleting, no bacterial resistance concerns)
- Highly cost effective; superior to competing technologies
- Ideally suited for a wide range of health care and consumer applications



Quick-Med's Technologies Destroy the Bacterial Cell Wall

Three Core Antimicrobial Technologies

- **NIMBUS®** – A family of novel, non-depleting, non-leaching antimicrobial compounds designed for a wide range of medical device applications, including wound dressings, catheters, films and coatings.

  Very large polymer / numerous bioactive groups / bonded to substrate

- ***Stay Fresh®*** – a unique chemical formulation for apparel and other laundered textiles with a durable antimicrobial agent effective against an array of bacteria even after 75 laundering cycles.

  Hydrogen peroxide biocide / highly durable to laundering / color safe

- **NimbuDerm™** – A novel copolymer for application as a persistent hand sanitizer with long lasting (6^{+} hour) protection against germs.

  Film former / bondable to skin

All Quick-Med antimicrobial technologies are: broadly effective, rapidly active, non-leaching, non-depleting, non toxic, and engineered to not to induce bacterial resistance

World Class Technology

Wound Healing Society

Blue Ribbon Industrial R&D Awards

2006 , 2008, 2010, 2011

TIME

Microbe-Busting Bandages

Innovators Forging the Future

"NIMBUS poses no danger of bacteria developing resistance, or of releasing toxic material into the wound and impeding the healing process. It is a novel technology: bonded and effective even in high concentrations of body fluid."

-Gregory Schultz, PhD
Professor, Institute for Wound Research
University of Florida

Past President, Wound Healing Society

Superior to Competing Technologies

We offer superior attributes …

Characteristic	Quick-Med	Silver	Triclosan
Effectiveness	**High**	High	Medium
Durability	**High**	Medium	Medium
Leaching	**No**	Yes	Yes
Bacterial Resistance Concerns	**No**	Documented	Documented
Economics	**Low Cost**	Expensive	Medium Cost

… while key competitors are receiving increased scrutiny

Silver

(the major active in medical devices)

- Impedes wound healing
- Susceptible to bacterial resistance
- Growing environmental concerns

Triclosan

(the major active in consumer products)

- Toxic to fish; found in 60% of US streams (USGS)
- Believed to be an endocrine disruptor
- Found in urine of 75% of population (CDC)
- Recent congressional action urging regulatory ban

Patent Protection in Major World Markets

Our technologies are protected by patents and patent applications in the United States, Australia, Brazil, Canada, China, Europe, India, Japan, Korea, Mexico, Russia, and South Africa

Medical Devices *(NIMBUS & NimbuDerm)*	• 5 U.S. and 8 foreign patents granted • 7 U.S. and 25 foreign patents pending *Granted patents expire in 2019, 2024 and 2028.*
Textiles *(Stay Fresh)*	• 2 U.S. and 2 foreign patents pending *Pending patents to provide protection until 2030*

Key competing technologies, triclosan and ionic silver, are off-patent

Business Model *High Margin, Low Infrastructure*

Strategic Thrust	Partnering with market leaders
Revenues	Recurring licensing fees
Cost of Sales	No manufacturing No inventory carrying costs
SG&A	Expenses focused on R&D No end-market sales force Core management team Legal & professional support
Income	Very profitable with high margins (> 60% gm) with sustainable recurring revenues

Partnering with Leaders

We are off to a strong start in partnering with market leaders and innovators in key target markets

- ✓ Traditional wound care licensee (US & Canada) – Derma Sciences

Future Launches

- ✓ Consumer/retail wound care licensee – leading global consumer healthcare company
- ✓ India wound care licensee – Viridis BioPharma
- ✓ Medical adhesives licensee – Avery Dennison
- ✓ Military uniforms

Development Programs

- ✓ Catheters – development completed with Foster/PolyMedex
- ✓ Advanced wound care and & medical devices – Multiple confidential programs

Development and Growth Strategy

	Intellectual Property	Product Proof of Concept	Regulatory Approval	Partners	Launch & Support
Medical Devices					
Traditional Wound Care	✓	✓	✓	✓	✓
Advanced Wound Care	✓	✓	In process	✓	
Incontinence Products	✓	In process			
Catheters	✓	✓		In process	
Textiles					
Medical Textiles	✓	✓	In process		
Essential Apparel	✓	✓	✓	In process	
Military Clothing	✓	✓	✓	✓	
Work Wear	✓	✓	✓		
Active Wear	✓	✓	✓		
Longer Term					
Hand Sanitizer	✓	✓			

Long Term End-Market Revenue Opportunity

Example

Wound Care Market	$14 Billion
% available to antimicrobial tech	20% to 30%
Antimicrobial Opportunity	$2.8 to $4.2 Billion
Share held by QMDT partners	20% to 25%
Partners end-market revenue	$560 to $1,050 Million
QMDT royalty rates (typical)	3% to 5%
QMDT revenue opportunity	$17 to $52 Million

The Quick-Med Opportunity

Technology superiority to capture a significant share of the antimicrobial space in each of several market segments

End Market	Global Market	% Antimicrobial (Penetration Potential)	QMT Revenue Opportunity *
Wound Care	$ 14 billion	20-30%	$ 17 – 52 million
Catheters	$ 13	10-30%	$ 13 – 39
Incontinence	$ 2	10-25%	$ 2 – 5
Medical Textiles	$ 2	20-30%	$ 4 – 6
Apparel	$ 34	5-10%	$ 17 – 34
Sanitizers	$ 2	100 %	$ 100 -200**
Total	**$65 billion**	**10 – 20 %**	**$ 153 – 336 million**

* Wound care assumptions per previous slide. Other segments assume commercialization partners with 25% market share and 4% average royalty rate

** Based on a product sale business model and 5-10% market share

Statement of Operations

Recurring royalty and license fees from initial licensee are ramping up. Additional licensees already in pipeline

	Fiscal Year Ended June 30,	
	2011	2010
Revenues		
Royalty and license fees	$ 303,256	$ 174,416
Research and development services	243,750	302,500
Product sales	492,572	517,027
	1,039,578	993,943
Expenses:		
Cost of product sales	23,932	23,370
Research and development	1,023,068	1,223,527
General and administrative expenses	1,652,570	1,499,866
Licensing and patent expenses	323,440	261,536
Depreciation and amortization	68,357	70,613
Total operating expenses	3,091,367	3,078,912
Income (loss) from operations	(2,051,789)	(2,084,969)

Capitalization Table

Capitalization Table as of June 30, 2011

Equity (100,000,000 authorized)	Issued Shares	Conversion or Exercise Price	Fully Diluted
Common Stock	37,246,154		37,246,154
$6.6 Million - 6% - 8% Senior Secured Convertible Notes due Dec. 2013 and June 2014		$0.19 - $1.00	14,993,888
Stock options, Expire between Dec. 2011 and Nov. , 2014		$0.20 - $1.05	4,794,270
Warrants, Expire between Dec. 2011 and Nov. , 2014	_____	$0.20 - $1.46	974,920
Total	37,246,154		58,009,232

Debt Summary

Short - term note	
Note payable – related party	$ 238,817
Long - term note	
Senior convertible notes[1] – related party	$5,337,565
Senior convertible note[2] – Institutional Investor	1,158,373
Senior convertible notes - Others	254,986
Note payable – Officer	93,941
Long - term debt	$ 6,844,865
Total debt (6/30/11)	$ 7,083,682

[1] Multiple notes. 6-8% interest rates. Conversion price ranges from $0.18 - $0.74 based on stock price at time of the advances were received. Maturity – 12/31/2013

[2] 8% interest rate. Conversion price = $0.60 Maturity – 12/31/2013

Investment Highlights

- Unique and cost-effective technology
- Solid patent protection
- Large market opportunities
- Initial regulatory approvals in place (FDA – 2009; EPA – 2011)
- Initial licensees and partnerships in place
- Growing market recognition of competition's shortcomings
- High margin business model, recurring revenue stream with low infrastructure needs
- Outstanding scientific team

Quick-Med Technologies, Inc.

Developing Next Generation Antimicrobial Technologies